Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.57 |
| ▸ | PPARG | P37231 | 7/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427770 | 0.89 | SMPD1 (0.44) | PPARAPPARGSMPD1 | |
| SCHEMBL5427774 | 0.85 | PPARA (0.42) | PPARAPPARG | |
| SCHEMBL5434600 | 0.84 | PPARG (0.63) | PPARAPPARGSMPD1P2RX4PPARD | |
| SCHEMBL5428115 | 0.83 | PPARA (0.56) | PPARAPPARGSMPD1P2RX4PPARD | |
| SCHEMBL5431844 | 0.82 | PPARG (0.44) | PPARAPPARGSMPD1RAB9A | |
| SCHEMBL6505582 | 0.82 | PPARG (0.54) | PPARAPPARGSMPD1PPARD | |
| SCHEMBL5438445 | 0.81 | MAPT (0.46) | PPARGRAB9A | |
| SCHEMBL5432386 | 0.80 | POLB (0.51) | RAB9A | |
| SCHEMBL5426375 | 0.80 | MAPT (0.47) | PPARAPPARG | |
| SCHEMBL5423631 | 0.79 | SMN1; SMN2 (0.53) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | PPARA 990/4885PPARG 615/4885SMPD1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.